Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Nimbus Therapeutics, LLC

News headline image
Nimbus Therapeutics to Present New Preclinical Data on Selective SIK2 Inhibition in Rheumatoid Arthritis at ACR Convergence 2026
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Strengthens Leadership Team to Support Next Phase of Growth
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Presents New Mechanistic Data Highlighting Differentiated Biology of Selective SIK2 Inhibitors at IMMUNOLOGY2026™
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics to Present Preclinical and Translational Data on Novel SIK2 Inhibitors at 21st Congress of European Crohn’s and Colitis Organisation (ECCO)
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Appoints Abbas Kazimi as Chief Executive Officer
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Achieves Research Milestone in Collaboration with Lilly
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Presents Positive Updated Data from Phase 1/2 Clinical Trial of HPK1 Inhibitor for Advanced Solid Tumors at SITC 39th Annual Meeting
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor NTX-452 at 36th EORTC-NCI-AACR Symposium
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics to Present First Preclinical Data from Werner Syndrome Helicase Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Appoints Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, Oncology
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Presents Positive Preliminary Data from Clinical Trial of HPK1 Inhibitor in Solid Tumors at SITC Annual Meeting
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines
From Nimbus Therapeutics, LLC
Via Business Wire
News headline image
Nimbus Therapeutics Announces Closing of Takeda’s Acquisition of TYK2 Subsidiary
From Nimbus Therapeutics, LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.